ISIS-4.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 7752783)

Published in Lancet on May 27, 1995

Authors

W R Herzog

Articles by these authors

Delayed-type hypersensitivity initiation by early-acting cells that are antigen mismatched or MHC incompatible with late-acting, delayed-type hypersensitivity effector T cells. J Immunol (1991) 1.02

Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft. Transplantation (1987) 0.95

Human cytotoxic T lymphocytes. I. Limiting-dilution analysis of alloreactive cytotoxic T-lymphocyte precursor frequencies. Scand J Immunol (1985) 0.94

Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol (1994) 0.91

Changes in the haemostatic profile during magnesium deficiency in swine. Magnes Res (1996) 0.81

Serotonin initiation of delayed-type hypersensitivity: mediation by a primitive Thy-1+ antigen-specific clone or by specific monoclonal IgE antibody. Skin Pharmacol (1991) 0.81

Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors. Pharmacol Res (1997) 0.80

Comparison of the effect of polymethylmethacrylate and silicone intraocular lenses on rabbit corneal endothelium in vitro. J Cataract Refract Surg (1987) 0.79

Inhibition of IL-2-dependent proliferation by a prostaglandin-dependent suppressor factor. J Immunol (1993) 0.79

Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro. J Mol Cell Immunol (1987) 0.78

Plasma fibronectin during myocardial ischemia-reperfusion: effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Am J Hematol (1998) 0.76

Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol (1997) 0.75

Magnesium and myocardial infarction. Lancet (1994) 0.75

Coenzyme Q10 protects ischemic myocardium in an open-chest swine model. Clin Investig (1993) 0.75

Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Blood Coagul Fibrinolysis (1996) 0.75

Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine. Int J Cardiol (1997) 0.75

Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine. J Cardiovasc Pharmacol (1996) 0.75

Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. Pharmacology (1996) 0.75

Serial changes of soluble endothelin-1 levels during myocardial ischaemia-reperfusion. Effects of magnesium, diltiazem and a novel MAC-1 inhibitor. Pharmacol Res (1998) 0.75

Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor? Mol Aspects Med (1997) 0.75

Hemostatic changes after dietary coenzyme Q10 supplementation in swine. J Cardiovasc Pharmacol (1996) 0.75

Deployment of a previously embolized, unexpanded, and disarticulated Palmaz-Schatz stent. Cathet Cardiovasc Diagn (1997) 0.75

Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine. Pharmacology (1996) 0.75

A canine model of acute coronary artery thrombosis for the evaluation of reperfusion strategies. Cardiology (1994) 0.75

Proline isomerism in the protein folding of ribonuclease A. J Biol Chem (1980) 0.75

Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction. Coron Artery Dis (1994) 0.75

Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Prostaglandins Leukot Essent Fatty Acids (1997) 0.75

Successful use of education and cost-based feedback strategies to reduce physician utilization of low-osmolality contrast agents in the cardiac catheterization laboratory. Am J Cardiol (1994) 0.75